RESUMO
This study reports on the latest advances in childhood headaches that have been made in the last few years, with special emphasis on the important new modifications that have been produced with respect to the previous ones, published in the beta version of the third edition of the International Classification of Headache Disorders. These include headaches that have undergone important qualifications, the appearance of new entities and a section which reports the existence of new headaches, but which have still not been considered as new entities. Additionally, other points that are highlighted include the strong relation between childhood headaches and attention deficit hyperactivity disorder, the weak relation between glutamate intake and the appearance of headaches, and the scant usefulness of magnetic resonance imaging of the brain in the diagnosis of these processes. Moreover, the new modification produced in childhood episodic syndromes is highlighted.
TITLE: Cefaleas infantiles: nuevos conceptos y recientes avances.En el presente trabajo se exponen los recientes avances sobre cefaleas infantiles que se han producido en los ultimos años, y se da una especial importancia a las nuevas e importantes modificaciones que se han producido con respecto a las anteriores, publicadas en la tercera edicion, version beta, de la clasificacion de la Sociedad Internacional de Cefaleas; entre ellas, cefaleas que han sufrido importantes matizaciones, la aparicion de nuevas entidades y un apartado en el que se recoge la existencia de nuevas cefaleas, pero que aun no se han considerado como nuevas entidades. Ademas, se resalta la fuerte relacion existente entre las cefaleas infantiles y el trastorno por deficit de atencion/hiperactividad, la poca relacion de la toma de glutamato con la aparicion de cefaleas y la escasa utilidad de la resonancia cerebral en el diagnostico de estos procesos. Por otra parte, se resalta la nueva modificacion producida en los sindromes episodicos de la infancia.
Assuntos
Cefaleia , Criança , Cefaleia/classificação , Cefaleia/complicações , Cefaleia/etiologia , HumanosRESUMO
INTRODUCTION: West syndrome is an age-specific form of epilepsy that associates infantile spasms, hypsarrhythmia and a delay in or the complete stoppage of psychomotor development, although this last case is not essential. AIMS: To define the profile of West syndrome in our environment by taking into account its aetiology, semiology, response to different therapeutic options and the appearance of side effects, as well as to establish prognostic factors that determine its course. PATIENTS AND METHODS: A data collection document stating the eligibility criteria was drafted. Data were collected by reviewing the medical records of patients diagnosed with West syndrome during the period between January 2003 and January 2009. Later, a statistical study was conducted with descriptive analysis and the level of statistical significance of the possible prognostic factors was established. RESULTS: The study included 70 patients. There was a predominance of symptomatic aetiology, with hypoxia-ischaemia as the main cause. Regardless of the aetiology, 58% of patients responded to treatment with vigabatrine. Over 80% of patients being treated with adrenocorticotropic hormone were finally seizure-free and without hypsarrhythmia. Almost half the patients progressed to other epilepsies. CONCLUSIONS: The statistically significant poor prognostic factors were: existence of a prenatal history, neonatal history, symptomatic aetiology, age of onset below 4 months, epileptic seizures before the onset of the spasms and outside the neonatal period, and delayed psychomotor development prior to the onset of the spasms.
Assuntos
Anticonvulsivantes/uso terapêutico , Espasmos Infantis , Hormônio Adrenocorticotrópico/uso terapêutico , Diagnóstico Diferencial , Eletroencefalografia , Feminino , Humanos , Hipóxia-Isquemia Encefálica/complicações , Lactente , Masculino , Prognóstico , Estudos Retrospectivos , Espasmos Infantis/etiologia , Espasmos Infantis/fisiopatologia , Espasmos Infantis/terapia , Resultado do Tratamento , Vigabatrina/uso terapêuticoRESUMO
INTRODUCTION: It is important to conduct studies on the utilization of new antiepileptic drugs in order to improve their use. Our objective is to describe the use patterns of carbamazepine and oxcarbazepine. METHODS: Observational, cross-sectional, national study with 58 investigators that included 185 pediatric patients with partial epilepsy. We recorded prescription patterns, quality of life (QoL) using the QoL scale in childhood epilepsy (CAVE) and use of resources. RESULTS: 134 patients were under treatment with oxcarbazepine (72.4 %), with a mean dose of 22.3 mg/kg/day; standard deviation (SD): 8.04; 95 % confidence interval (CI): 20.9 to 23.7, and 51 (27.6%) with carbamazepine, mean dose of 14 mg/kg/day; SD: 6.2; 95 % CI: 12.3 to 15.8. A total of 19.4% and 21.6 %, respectively, followed multiple drug treatment. The mean scores on functional dimensions of CAVE were (out of 5): school attendance: 4.5; SD: 0.7; social relationships: 4.1; SD: 0.9, and autonomy: 3.9; SD: 1.9. Patients receiving multiple drug therapy had worse results in quality of life (p < 0.0001) and greater utilization of health care resources, more visits to the specialists (p = 0.04) and to the emergency departments (32.4% vs 7.4%). CONCLUSIONS: Oxcarbazepine is used in lower doses than recommended and the dosing is not adjusted for weight. Underdosing may lead to regimes of multiple drug therapy that should be reviewed individually.
Assuntos
Anticonvulsivantes/uso terapêutico , Carbamazepina/análogos & derivados , Carbamazepina/uso terapêutico , Epilepsias Parciais/tratamento farmacológico , Adolescente , Criança , Estudos Transversais , Feminino , Guias como Assunto , Humanos , Masculino , Oxcarbazepina , Qualidade de Vida , Espanha , Resultado do TratamentoRESUMO
INTRODUCTION: About 30% of epileptic patients suffer from drug-resistant epilepsy (DRE). Quality of life is worse and costs are higher than in controlled epilepsy. One of the aims of the LINCE study was to assess the prevalence of DRE in epilepsy-specialized and general neurology clinics in Spain and the clinical management of these patients in routine clinical practice. PATIENTS AND METHODS: Cross-sectional, retrospective study to evaluate clinical prevalence and cost of DRE in Spain. Every participant neurologist assessed the percentage of DRE among the first 40 patients with diagnosed epilepsy seen. Patients of both sexes, older than 18 years were recruited. Their treatment before and after DRE diagnosis was analyzed. RESULTS: DRE prevalence in Spain is 22.7% (36% in epilepsy-specialized and 18.5% in neurology clinics; p < 0.0001), with no differences between genders. More than 50% of these patients have hardly achieved a secondary education and only 44% are employed. The most frequent drugs used after DRE diagnosis are lamotrigine (33.5%), levetiracetam (32.4%), carbamazepine (31.9%) and topiramate (25.8%) in various combinations, but the highest efficacy (equal or more than 50% seizures reduction) is obtained with pregabaline (53.1%), oxcarbazepine (50.6%) and levetiracetam (49.5%) and topiramate (48%). CONCLUSIONS: 22.7% of epileptic outpatients in Spain are diagnosed with DRE in clinics of neurology. These will require certain social interventions and greater use of health resources, including treatment with more appropriate AEDs. Pregabaline, oxcarbazepine, levetiracetam and topiramate are among the most effective AEDs in this type of patients.
Assuntos
Anticonvulsivantes/uso terapêutico , Resistência a Medicamentos , Epilepsia , Departamentos Hospitalares , Ambulatório Hospitalar , Adulto , Estudos Transversais , Epilepsia/tratamento farmacológico , Epilepsia/fisiopatologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Neurologia , Qualidade de Vida , Estudos Retrospectivos , EspanhaRESUMO
BACKGROUND: Convulsions with mild rotavirus gastroenteritis were first described by Morooka in 1982. This is a process of convulsions and gastroenteritis without any changes in complementary tests. They are few cases out of Asia and they are rarely reported in Spain. CLINICAL CASE: They were 2 infants, 4 and 7 months old with no background of interest who suffered from status epilepticus during a mild rotavirus gastroenteritis without resolution after treatment. CONCLUSIONS: Benign afebrile cluster convulsions with rotavirus gastroenteritis is not common and is not often diagnosed in our area. It should be included in the differential diagnosis of status epilepticus and it is crucial to look for a history of diarrhoea. Careful management of diagnosis and treatment is essential given its controversial character.
Assuntos
Gastroenterite/complicações , Gastroenterite/virologia , Infecções por Rotavirus/complicações , Estado Epiléptico/etiologia , Humanos , Lactente , Masculino , Índice de Gravidade de DoençaRESUMO
INTRODUCTION: Angelman syndrome (AS) is a heterogeneous genetically-based disorder that is characterised by severe mental retardation, absence of language, ataxia, craniofacial dysmorphia and a characteristic behavioural phenotype. PATIENTS AND METHODS: We analyse 12 patients with a mean age of 10.9 years diagnosed with AS. The study focuses on the characteristics of epilepsy and attempts to correlate the findings with the genotype of the disease. RESULTS: All the patients presented early-onset generalised seizures and all except one had polymorphic seizures. Eight of them also presented focal seizures. All the patients displayed electroencephalographic alterations before the age of two years. Although there are no pathognomonic abnormalities in the electroencephalogram (EEG), knowledge of them in AS can be an important element of assessment for reaching an early diagnosis of this condition. In our series, all the patients with 15q11-13 deletion presented an EEG pattern that was typical of the disease. The most commonly used and most effective antiepileptic drug was valproic acid (used in all patients), followed by lamotrigine and clobazam. Up to 10 antiepileptic drugs had been tried in some patients. Epilepsy usually has a very early onset and even precedes the diagnosis of AS in most cases, which means that the epileptic seizures can be an important aid in reaching an early diagnosis. Suitable classification of such seizures is essential. CONCLUSIONS: AS must be considered as a differential diagnosis in children who present early severe epilepsy together with psychomotor retardation and important gait and language disorders. This diagnosis is backed by the typical findings in the EEG.
Assuntos
Síndrome de Angelman/complicações , Epilepsia/etiologia , Adolescente , Adulto , Criança , Pré-Escolar , Feminino , Humanos , MasculinoRESUMO
INTRODUCTION: The health outcomes research methodology is especially important for evaluating therapeutic efficiency and effectiveness in the case of patients with epilepsy. AIM: To describe the patterns of utilisation of carbamazepine and the new antiepileptic drug oxcarbazepine, as well as their relation with the quality of life (patient's satisfaction and social and occupational repercussion) and therapeutic efficiency (utilisation of health care resources). PATIENTS AND METHODS: We performed an observational study of 284 adult patients with partial epilepsy that was clinically controlled with carbamazepine or oxcarbazepine either in monotherapy or with the addition of some other pharmaceutical agent. The study was carried out using the Morisky-Green questionnaire (for therapeutic compliance), the Sheehan Disability Scale (SDS, social functioning) and direct questioning (patient satisfaction); therapeutic efficiency was assessed with the register of medical visits, complementary examinations and concomitant treatments. RESULTS: The study showed that 65.6% suffered from partial seizures of a single type (simple, complex or with secondary generalisation) and 34.4% had several types of seizures. Oxcarbazepine treatment was being administered to 52% (mean dose: 1134.4 mg/day) and 48% were receiving carbamazepine (mean dose: 876.3 mg/day). The SDS scores were: occupational: 2.1; social: 2.0; and familial: 1.4. Most of the patients admitted having skipped some doses under certain circumstances; for this reason, 98.9% of them presented a medium level of compliance. It was found that 8.5% of patients visited the emergency department and 3% used hospitalisation services. CONCLUSIONS: The doses of oxcarbazepine tended to be lower than those recommended on the patient information leaflet. Patients only consider themselves to be mildly affected in their social and occupational relations and are satisfied with the control of their seizures. Patients receiving combination therapy utilise more health care resources.
Assuntos
Anticonvulsivantes/uso terapêutico , Carbamazepina/análogos & derivados , Carbamazepina/uso terapêutico , Epilepsias Parciais/tratamento farmacológico , Adolescente , Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Oxcarbazepina , Padrões de Prática Médica , Qualidade de Vida , Espanha , Resultado do TratamentoRESUMO
INTRODUCTION: Levetiracetam (LEV) is the latest drug approved in the European Union for use in polytherapy in children over 4 years of age with partial epileptic seizures that are resistant to other antiepileptic drugs. AIM. To report our experience of associating LEV in children with medication resistant epileptic seizures. PATIENTS AND METHODS: We conducted an open, observational, respective study involving 133 children with refractory epilepsies: 106 with focal seizures and 27 with other types of seizures. LEV was associated over a period of more than 6 months and we evaluated its repercussion on the frequency of the seizures and the side effects related to the drug. RESULTS: With average doses of LEV of 1,192 +/- 749 mg/day the frequency of the seizures was reduced by over 50% in 58.6% of cases and seizures were quelled in 15.8% of patients. Side effects were produced in 27.8% of cases, and were usually transient or tolerable; these effects led to withdrawal of LEV in only eight cases (6.02%). In 37 children (27.8%), their relatives noted an improvement in their social behaviour and cognitive abilities. CONCLUSIONS: a) LEV is an effective drug that is well tolerated in children with refractory epilepsy; b) Its effectiveness in different types of seizures indicates a broad therapeutic spectrum; and c) LEV can even condition favourable secondary effects, a circumstance that has been reported only exceptionally in the case of other antiepileptic drugs.
Assuntos
Anticonvulsivantes/uso terapêutico , Epilepsia/tratamento farmacológico , Piracetam/análogos & derivados , Adolescente , Criança , Pré-Escolar , Resistência a Medicamentos , Feminino , Humanos , Levetiracetam , Masculino , Piracetam/uso terapêutico , Estudos RetrospectivosRESUMO
AIM: To use a model of economic evaluation to analyse the efficiency of therapy with the antiepileptic drugs indicated in recently diagnosed partial and generalised epilepsy. MATERIALS AND METHODS: The treatment of partial epilepsy and generalised epilepsy in Spain was taken as the basis to design two flexible simulation models of the decision tree type. The time horizon of the study was one year and the perspective was that of the Spanish National Health System, and indirect costs were also included. Clinical effectiveness data were obtained from a review of the literature on clinical trials. Information about resources was obtained from the opinions of a panel of experts. Unitary costs of resources were drawn from Spanish databases (euro 2003). The findings of the study were expressed in terms of average cost per patient with each therapeutic strategy, as well as the incremental cost of the different treatment strategies with respect to valproic acid. RESULTS: According to the literature that was reviewed, there are no differences in effectiveness from one antiepileptic drug to another. The incremental cost of the different therapeutic strategies, with respect to valproic acid, lies between 211 and 911 euros per patient and year in partial epilepsy, and between 1,355 and 1,297 euros per patient and year in the case of generalised epilepsy. CONCLUSIONS: The use of sustained-release valproic acid in recently diagnosed partial and generalised epilepsy would allow savings to be made in resources, with respect to the other antiepileptic drugs, and can therefore be considered to be the most effective therapeutic option.
Assuntos
Anticonvulsivantes , Custos de Medicamentos , Epilepsia , Anticonvulsivantes/economia , Anticonvulsivantes/uso terapêutico , Efeitos Psicossociais da Doença , Análise Custo-Benefício , Tomada de Decisões , Farmacoeconomia , Epilepsia/tratamento farmacológico , Epilepsia/economia , Humanos , Modelos Econométricos , Resultado do TratamentoRESUMO
AIMS: The objective of this work was to produce a scientific evidence-based guide to clinical practice dealing with the basic questions concerning the treatment of epilepsy. DEVELOPMENT: A committee of 11 experts belonging to the Andalusia Epilepsy Society, made up of six neurologists, three neuropaediatricians, one neurosurgeon and a pharmacologist, all of whom were deeply involved and experienced in epilepsy, conducted a thorough review of the literature in search of all the evidence available on the proposed subject matter. The following databases were used: MEDLINE, Cochrane Library and the databases of several clinical practice guidelines (National Guideline Clearinghouse, National Institute of Clinical Excellence and the American Academy of Neurology's Clinical Guidelines). The Guide was set out in seven sections and was published in four parts. From a total number of 187 relevant documents, the committee found 63 examples of scientific evidence and 91 therapeutic recommendations. These were tabulated and classified according to the European Federation of Neurological Societies' criteria for producing Clinical Practice Guidelines. CONCLUSIONS: The results of this survey provide scientific evidence-based clinical guidelines that are useful, simple and applicable at different levels of health care.
Assuntos
Anticonvulsivantes/uso terapêutico , Epilepsia/tratamento farmacológico , Guias como Assunto , Adulto , Criança , Pré-Escolar , Bases de Dados Factuais , Medicina Baseada em Evidências , Humanos , Lactente , EspanhaRESUMO
AIMS: The objective of this work was to produce a scientific evidence-based guide to clinical practice dealing with the basic questions concerning the treatment of epilepsy. DEVELOPMENT: A committee of 11 experts belonging to the Andalusia Epilepsy Society, made up of six neurologists, three neuropaediatricians, one neurosurgeon and a pharmacologist, all of whom were deeply involved and experienced in epilepsy, conducted a thorough review of the literature in search of all the evidence available on the proposed subject matter. The following databases were used: MEDLINE, Cochrane Library and the databases of several clinical practice guidelines (National Guideline Clearinghouse, National Institute of Clinical Excellence and the American Academy of Neurology's Clinical Guidelines). The Guide was set out in seven sections and was published in four parts. From a total number of 187 relevant documents, the committee found 63 examples of scientific evidence and 91 therapeutic recommendations. These were tabulated and classified according to the European Federation of Neurological Societies' criteria for producing Clinical Practice Guidelines. CONCLUSIONS: The results of this survey provide scientific evidence-based clinical guidelines that are useful, simple and applicable at different levels of health care.
Assuntos
Anticonvulsivantes/uso terapêutico , Resistência a Medicamentos , Epilepsia/terapia , Neurologia/métodos , Encéfalo/fisiopatologia , Encéfalo/cirurgia , Terapia Combinada , Terapia por Estimulação Elétrica , Epilepsia/fisiopatologia , Epilepsia do Lobo Temporal/cirurgia , Lateralidade Funcional/fisiologia , Humanos , Procedimentos Neurocirúrgicos/métodos , Espanha , Nervo Vago/fisiologiaRESUMO
AIMS: The objective of this work was to produce a scientific evidence-based guide to clinical practice dealing with the basic questions concerning the treatment of epilepsy. DEVELOPMENT: A committee of 11 experts belonging to the Andalusia Epilepsy Society, made up of six neurologists, three neuropaediatricians, one neurosurgeon and a pharmacologist, all of whom were deeply involved and experienced in epilepsy, conducted a thorough review of the literature in search of all the evidence available on the proposed subject matter. The following databases were used: MEDLINE, Cochrane Library and the databases of several clinical practice guidelines (National Guideline Clearinghouse, National Institute of Clinical Excellence and the American Academy of Neurology's Clinical Guidelines). The Guide was set out in seven sections and was published in four parts. From a total number of 187 relevant documents, the committee found 63 examples of scientific evidence and 91 therapeutic recommendations. These were tabulated and classified according to the European Federation of Neurological Societies' criteria for producing Clinical Practice Guidelines. CONCLUSIONS: The results of this survey provide scientific evidence-based clinical guidelines that are useful, simple and applicable at different levels of health care.
Assuntos
Anticonvulsivantes/uso terapêutico , Epilepsia/tratamento farmacológico , Anormalidades Induzidas por Medicamentos/etiologia , Idoso , Anticonvulsivantes/administração & dosagem , Anticonvulsivantes/efeitos adversos , Anticonvulsivantes/farmacocinética , Encefalopatias/complicações , Anticoncepcionais Orais Hormonais/farmacocinética , Interações Medicamentosas , Quimioterapia Combinada , Epilepsia/complicações , Medicina Baseada em Evidências , Feminino , Rejeição de Enxerto/tratamento farmacológico , Infecções por HIV/complicações , Hemorragia/induzido quimicamente , Humanos , Imunossupressores/farmacocinética , Nefropatias/complicações , Nefropatias/metabolismo , Hepatopatias/complicações , Masculino , Porfirias/complicações , Gravidez , Complicações na Gravidez/tratamento farmacológico , Efeitos Tardios da Exposição Pré-Natal , Doenças Respiratórias/complicações , Convulsões Febris/tratamento farmacológico , Estado Epiléptico/tratamento farmacológicoRESUMO
AIMS: The objective of this work was to produce a scientific evidence-based guide to clinical practice dealing with the basic questions concerning the treatment of epilepsy. DEVELOPMENT: A committee of 11 experts belonging to the Andalusia Epilepsy Society, made up of six neurologists, three neuropaediatricians, one neurosurgeon and a pharmacologist, all of whom were deeply involved and experienced in epilepsy, conducted a thorough review of the literature in search of all the evidence available on the proposed subject matter. The following databases were used: MEDLINE, Cochrane Library and the databases of several clinical practice guidelines (National Guideline Clearinghouse, National Institute of Clinical Excellence and the American Academy of Neurology's Clinical Guidelines). The Guide was set out in seven sections and was published in four parts. From a total number of 187 relevant documents, the committee found 63 examples of scientific evidence and 91 therapeutic recommendations. These were tabulated and classified according to the European Federation of Neurological Societies' criteria for producing Clinical Practice Guidelines. CONCLUSIONS: The results of this survey provide scientific evidence-based clinical guidelines that are useful, simple and applicable at different levels of health care.
Assuntos
Anticonvulsivantes/uso terapêutico , Epilepsia/tratamento farmacológico , Guias de Prática Clínica como Assunto , Bases de Dados Factuais , Medicina Baseada em Evidências , Humanos , EspanhaRESUMO
INTRODUCTION: Levetiracetam (LEV) is the latest antiepileptic drug (AED) to be marketed, and is indicated for use in association in adults with focal seizures. AIMS: The purpose of this study is to report on our experience of administering LEV to children and adolescents with pharmacoresistant epilepsies. PATIENTS AND METHODS: Retrospective open trial involving the observation of 43 children and adolescents with refractory epilepsies, using associated LEV for more than 6 months on an individual basis, the aim of which was to evaluate the repercussions on the frequency of the seizures, together with the adverse and beneficial side effects of LEV administration. RESULTS: With mean doses of LEV of 45.01 +/- 33.02 mg/kg/day the frequency of seizures was reduced by >50% in 65% of patients, while seizures were completely eradicated in 14% of patients; adverse side effects were reported in 28% of patients, although these were usually transient or tolerable, as LEV administration only had to be stopped for this reason in two cases (4.65%). Relatives noted an improvement in social behaviour and in cognitive skills in the case of 15 children (34.9%). CONCLUSIONS: 1. LEV is an effective drug that is well tolerated in children and adolescents with refractory epilepsies; 2. Its effectiveness in different types of seizures suggests a broad therapeutic spectrum; 3. LEV is a well tolerated drug with favourable side effects, a fact that is rarely reported with regard to other AED.